Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MC4R | P32245 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21708593 | 0.91 | CES2 (0.34) | MAPT | |
| SCHEMBL21708517 | 0.90 | PTGFR (0.35) | PTGFRSLC6A3GAAMAPT | |
| SCHEMBL21708509 | 0.87 | NISCH (0.36) | PTGFRL3MBTL1GAA | |
| Hydrochloric Acid SCHEMBL21708570 | 0.86 | NISCH (0.35) | PTGFRL3MBTL1GAA | |
| SCHEMBL21708700 | 0.84 | CES2 (0.34) | PTGFR | |
| SCHEMBL21708481 | 0.82 | GAA (0.32) | PTGFRL3MBTL1GAA | |
| SCHEMBL21708464 | 0.82 | PTGFR (0.35) | PTGFRL3MBTL1MC4R | |
| SCHEMBL21708569 | 0.82 | KMT2A (0.33) | PTGFRL3MBTL1SLC6A3MDM2 | |
| SCHEMBL21708612 | 0.81 | TAS1R3 (0.32) | L3MBTL1GAA | |
| SCHEMBL21708658 | 0.81 | TAS1R3 (0.34) | PTGFRGAAMC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3609869-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | Bayer Aktiengesellschaft (DE) | 2020-02-19 | — | — | EP | disclosed |
| EP-3609870-A1 | SUBSTITUTED N-ARYLETHYL-2-AMINOQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | Bayer Aktiengesellschaft (DE) | 2020-02-19 | — | — | EP | disclosed |